Plenary Speaker

Ron Wange, PhD

Principal Consultant @ Aclairo Pharmaceutical Development Group

Title TBA

 Plenary Speaker

Jack Uetrecht, MD, PhD

Professor of Pharmacy & Medicine @ University of Toronto

DILI Risk Prediction: Focus on Mechanism

Riya Sharma, PhD

Senior Scientist, R&D @ STEMCELL Technologies

Intestinal and Hepatic Organoid Systems: In Vitro Models of Drug Toxicity

Sophie Tourdot, PhD

Immunogenicity Sciences Lead @ Pfizer

Hapten/ADA response and state of ADA in tox - Title TBA

Russell Naven, PhD

Head, Predictive Safety Data Exploration @ Novartis

Redefining How We Discover Safer Medicines with AI and NAMs

Matt Wagoner, PhD

Global Head of Investigative Toxicology @ Takeda Pharmaceuticals

AI-enabled Prediction of DILI with Transcriptomics

Radhakrishna Sura, PhD, DABT, DACVP

Senior Director, Nonclinical Safety and Pathobiology @ Gilead Sciences, Inc.

New Approach Methodologies (NAMs): Role of Nonclinical Scientists

Zhechu Peng, PhD, DABT

Director Project Toxicologist Immune Safety @ AstraZeneca

in vitro only toxicology package for a T-cell engagers across 2 indications - title TBA

Giel Hendriks, PhD

CEO @ Toxys Inc.

In Vitro Developmental Toxicity Testing of PROteolysis-Targeting Chimeras (PROTACs)

Kim Rockley

 @ AconiX

Benefits of Early In Vitro Screening for Seizure Liability in Problem Solving and Decision Making

Kaushik Datta, PhD, DABT

Distinguished Scientist and Therapeutic Area Lead @ Merck

IQ Survey - Strategies to Reduce NHP Use in the Nonclinical Development of Oncology Therapeutics 

Petra Lutterbuese, PhD, DABT

Principal Scientist @ Amgen (Munich)

Alternative Approaches During T Cell Engager Development: Regulatory Interactions, Scientific Rigor, and Reduced NHP Usage

Sheroy Minocherhomji, PhD, ERT, FRSB

Senior Director, Nonclinical Safety and Toxicology @ Eli Lilly and Company

Nonclinical Developmental Considerations of RNA-based Complex Biologics

Rhiannon Hardwick, PhD, DABT

Scientific Director, Discovery Toxicology @ Bristol Myers Squibb 

tox strategies /in vitro species selection and off-target profiling and how that leads into in vivo PD profiling and off-target assessment - title TBA

Wei Wang, PhD, DABT

Director @ Eli Lilly

tox profiles of GLP-1 agonists and oral peptides - Title TBA

John Vahle, PhD, DVM

Senior Research Fellow @ Eli Lilly

Addressing Safety Concerns of GLP-1 Receptor Agonists - A Case Study

Marie Lemper, PharmD, PhD, DABT, ERT, MSc

Head of US Toxicology @ UCB

Lost In Translation: From ePPND Study to Label

Qi Sun, ScD, M.D.

Associate Professor in the Departments of Nutrition & Epidemiology, Harvard T.H. Chan School of Public Health 

Body Weight Modulation: Contributors and Cardiometabolic Health Consequences 

Matthew Lalonde, PhD, DABT

Director Toxicology @ Kymera Therapeutics

In vitro/in vivo DART with KT-474- Talk title TBA

Nirav Patel, PhD

Global Head of Immune Oncology Safety Science @ AstraZeneca

Integrating T-Cell Engagers: Evolution, Preclinical Safety Packages in Oncology

Ryan Polli, PhD

Associate Director, PK Sciences @ Novartis Institute for Biomedical Research 

&

Kavita Raman, PhD

Sr. Principal Scientist II (Assoc. Director) @ Johnson & Johnson Innovative Medicine

Joint Presentation: T Cell Engagers for No-Oncology Indications: Bench to Bedside Considerations for Dose and Safety

Rebecca Kohnken, DVM, PhD, DACVP

Senior Principal Pathologist @ AbbVie

Use of NAMs to Support Early Safety Assessment in Drug Development 

 Spotlight Talk

Runxi Shen, PhD

Postdoctoral Associate, Broad Institute of MIT and Harvard

From Cell Morphology to Human Safety: Predicting Liver Toxicity Across Cell Types Using Cell Painting and Machine Learning

Onyi Irrechukwu, PhD, DABT

Associate Scientific Director @ Johnson & Johnson Innovation Medicine

Insights from Evaluations of Two Next-generation Trastuzumab Auristatin Conjugates - Trastuzumab-MMAU and Trastuzumab-AS269

 Lise Loberg, PhD, DABT

Senior Research Fellow @ AbbVie

Talk title TBA

Tracey Papenfuss, PhD

Senior Pathologist, Immune Service Lead @ StageBio

Talk title TBD

 Ramon Flores Pons, PhD

Lead Product Manager @ Clarivate

AI-powered Translational Safety Intelligence to Anticipate Drug Safety

 Bill Coode, PhD

Senior Business Development Executive @ Southern Research

Southern Research Institute: The Oldest US CRO?